Roche (RHHBY) said it is ready to immediately resume new orders and shipments of Sarepta’s (SRPT) Elevidys for ambulatory patients outside of the U.S. following the FDA’s decision to remove the voluntary hold on Elevidys for ambulatory Duchenne Muscular Dystrophy patients in the U.S., according to Bloomberg, citing an emailed statement from Roche.
Claim 55% Off TipRanks
Forget margin or options. Here's how the pros trade SRPTPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Barclays upgrades Sarepta to Equal Weight with worst-case ‘off the table’
- Sarepta upgraded to Equal Weight from Underweight at Barclays
- Sarepta upgraded, Tapestry downgraded: Wall Street’s top analyst calls
- Morning Movers: Boeing, P&G advance after earnings
- Video: Boeing results, dealmaking highlight busy morning